Vairavan Latha 4
4 · Arcutis Biotherapeutics, Inc. · Filed May 13, 2026
Research Summary
AI-generated summary of this filing
Arcutis (ARQT) CFO Vairavan Latha Sells 435 Shares
What Happened
Vairavan Latha, Chief Financial Officer of Arcutis Biotherapeutics (ARQT), reported an open-market sale of 435 shares on 2026-05-11 at $21.05 per share, for proceeds of $9,157. The filing indicates the sale was to cover tax withholding obligations tied to the vesting of restricted stock units (RSUs), not a discretionary cash-sale for investment purposes.
Key Details
- Transaction type: Sale (S) — open market/private sale reported on Form 4.
- Date of transaction: 2026-05-11; Form 4 filed: 2026-05-13 (within typical Form 4 deadline).
- Price and amount: 435 shares @ $21.05 ⇒ total proceeds ≈ $9,157.
- Footnote: F1 — sale was to cover tax withholding from RSU vesting.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Accession: 0002065881-26-000004 (Form 4 filed with the SEC).
Context
Sales to cover tax withholding after RSU vesting are common and generally considered routine administrative transactions rather than clear signals of insider bearishness. For retail investors, a small, tax-related sale like this is typically less informative than voluntary purchases by insiders.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-05-11$21.05/sh−435$9,157→ 85,978 total
Footnotes (1)
- [F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.